Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute Carrier Family 29 Member 1 (SLC29A1)
- Target
- SLC29A1
- Molecular classification
- Transporter, Solute Carrier Family
01
Overview
Solute carrier family 29 member 1 (SLC29A1), also known as Equilibrative Nucleoside Transporter 1 (ENT1), is a transmembrane glycoprotein that mediates the cellular uptake of nucleosides across plasma and mitochondrial membranes. It is a key member of the equilibrative nucleoside transporter family, facilitating sodium-independent transport of nucleosides such as adenosine, guanosine, inosine, uridine, and thymidine. ENT1 plays critical roles in the uptake of physiological nucleosides, cellular uptake of cytotoxic nucleoside analogs used in cancer chemotherapy or antiviral therapy, and modulation of extracellular adenosine concentrations. Mutations or variants in SLC29A1/ENT1 are associated with H syndrome, pigmented hypertrichosis with insulin-dependent diabetes, Faisalabad histiocytosis, and Augustine blood group system related hemolytic reactions.
- Other names
- ENT1Equilibrative Nucleoside Transporter 1Augustine blood group system
02
Mechanism of action
Equilibrative, sodium-independent nucleoside transport; Inhibition by NBMPR
03
Biological functions
Nucleoside transportNucleotide synthesisModulation of extracellular adenosine concentrations
04
Disease associations
H syndromePigmented hypertrichosis with insulin-dependent diabetesFaisalabad histiocytosisAcute hemolytic transfusion reactionsHemolytic disease in fetuses/newborns
05
Safety considerations
Immunogenicity related to Augustine blood group system, leading to hemolytic transfusion reactions or hemolytic disease of the fetus and newborn.Potential for altered drug response due to genetic variations in SLC29A1.
06
Interacting drugs
Nitrobenzylmercaptopurine ribonucleoside (NBMPR)
1 more in the full profile.
Beyond the preview
Go deeper on Solute Carrier Family 29 Member 1 (SLC29A1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute Carrier Family 29 Member 1 (SLC29A1).